Terence Kelly appointed CEO of ATAI platform company Perception Neuroscience

Today, ATAI Life Sciences, a global biotech platform that envisions an end to mental illnesses, announced the appointment of Dr. Terence Kelly as Chief Executive Officer of Perception Neuroscience, an ATAI biopharmaceutical company developing arketamine for treatment resistant depression. “Terry brings almost 30 years of R&D experience to the platform,” said Florian Brand, CEO, ATAI […]

ATAI Life Sciences Announces Joint Venture with DemeRx to Develop Ibogaine For Opioid Use Disorder

BERLIN and MIAMI, Jan. 24, 2020 /PRNewswire/ — ATAI Life Sciences AG (“ATAI” or the “Company”), a global biotech platform that envisions an end to mental illnesses, today announced an investment in two separate joint ventures (JV) with DemeRx, a clinical stage pharmaceutical company focused on developing ibogaine and noribogaine for the treatment of opioid use disorder (OUD). OUD represents a […]

Reflections on the progress of psychedelic medicine

Since co-founding ATAI Life Sciences, I’ve been a firm believer in the power of psychedelic medicine to transform the way we understand and treat mental health disorders. We’ve had much to be thankful for over the course of the past few years, but lately I’ve become acutely aware that we’ve turned a corner as a […]

ATAI’s Chief Scientific Officer addresses the future of psychiatric drug development at ISAD19

Last week, Srinivas Rao, Chief Scientific Officer of ATAI Life Sciences, spoke at the 10th Conference of the International Society for Affective Disorders (ISAD19), an important gathering of the European affective disorders expert community. This year’s programme addressed fundamental, clinical and translational issues in affective disorders, with experts from around the world travelling to London […]

ATAI Life Sciences and Cyclica launch joint venture to revolutionize drug development for mental health disorders

Berlin and Toronto, November11, 2019 ATAI Life Sciences AG, a global biotech platform that envisions an end to mental illnesses, and Cyclica Inc., a leading biotechnology company that leverages artificial intelligence and computational biophysics to streamline the drug discovery process, have launched a joint venture aimed at changing the paradigm in which mental health disorders […]

Social Comparisons: Effects on Mental Health

As a society becomes more and more unequal, status anxiety increases across all income deciles, not just the poor. People tend to worry more about whether or not they appear as successful or as a failure, causing considerable stress around work and social situations. Regardless of an individual’s level of income, how income is distributed […]

Gender Disparities and Mental Health Risk Factors

Gender greatly influences the power that males and females have over socio-economic factors that influence their mental health, social position and status, treatment in society, and sensitivity and exposure to certain mental health risks.  A few of the risk factors for common mental disorders that disproportionately affect women include low income, high income inequality, low […]

Inequality: An overlooked contributor to mental health disorders

Most people are aware of common risk factors for mental illness, such as genetics, adverse life events, and substance abuse. But there are a number of less obvious and less talked about influences at play when it comes to the mental health of populations across the world — one of these is inequality. Societal inequality is […]

Impact of the Depression Epidemic: Family & Community

Depression is today’s most prevalent mental health disorder and the leading cause of disability worldwide. However, the pain and burdens of depression are not limited to those diagnosed. Depression profoundly impacts the lives of those close to the affected person, from friends and family to co-workers and acquaintances. With 322 million people (4.4% of the […]

Let’s take a closer look at psilocybin

“Magic mushrooms” have officially entered the mainstream. Proponents in the media now regularly extol their potential for alleviating depression, addiction, and a host of other mental health issues, often linking their ongoing prohibition to a government PR blitz in the 60s and 70s. Today, psilocybin is the most commonly used psychedelic among people 34 and younger. But […]

ATAI’s Chief Scientific Officer joins leaders in psychedelic medicine at Mapping the Mind

Last week, Srinivas Rao, MD, Chief Scientific Officer of ATAI Life Sciences, took to the stage alongside other leaders in psychedelic medicine at the 2019 Mapping the Mind conference in Toronto. The conference, which featured speakers like Dr. David Nichols, founding president of the Heffter Insitute, and Dr. Matthew Johnson, associate director of the Johns […]

Burdens of Depression on the Individual

Depression is today’s most prevalent mental health disorder and the leading cause of disability worldwide. Painful both mentally and physically, the onset of the disease is slow and gradual, with highly variable symptoms that manifest differently from person to person, making it a challenge to identify for both medical practitioners and those close to the […]

Digital Depression – The Modern Dilemma

The last twenty years – the digital age – have fundamentally changed the way we interact with those around us, our surroundings and, perhaps most importantly, ourselves. In fact, one could argue that the last ten years –  the smartphone age – have had a deeper impact on human behavior than the last several centuries. […]

Consequences of the Youth Mental Health Crisis

Adolescents and young adults who suffer from mental disorders often face other long-term health consequences stemming from their diseases. When it comes to depression, for example, studies have shown that: Depression is commonly associated with other illnesses. In the 2018 Health of America Report published by Blue Cross Blue Shield, researchers found that it was […]